Download PDF
Semin Reprod Med 2001; 19(4): 373-380
DOI: 10.1055/s-2001-18645
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Transdermal Contraception

George W. Creasy, Larry S. Abrams, Alan C. Fisher
  • The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey
Further Information

Publication History

Publication Date:
29 November 2001 (online)

    Permissions and Reprints

ABSTRACT

This review summarizes the clinical studies involving the once-weekly Ortho Evra℗ (U.S. trademark)/Evra℗ (E.U. trademark) contraceptive patch. The patch delivers norelgestromin (NGMN), 150 μg, and ethinyl estradiol (EE), 20 μg, daily to the systemic circulation. The contraceptive patch provided ovulation suppression and cycle control similar to that of oral norgestimate 250 μg/EE 35 μg, significantly decreased mean maximum follicular diameter following a 3-day intentional delayed dosing phase when compared with oral levonorgestrel (LNG) 50/75/125 μg/EE 30/40/30 μg and oral LNG 100 μg/EE 20 μg, and was as effective as oral LNG 50/75/125 μg/EE 30/40/30 μg and oral desogestrel 150 μg/EE 20 μg in altering cervical mucus composition (i.e., creating a scanty, viscous consistency). The contraceptive patch provided efficacy, cycle control, and safety comparable to that seen with oral LNG 50/75/125 μg/EE 30/40/30 μg, but women were able to correctly follow the weekly dosing regimen significantly more often than the daily oral contraceptive dosing regimen. Less than 2% of patches were replaced because of complete detachment in these trials. The patch was not associated with phototoxicity or photoallergy. The contraceptive patch, the only noninvasive, weekly birth control method that a woman can self-administer, will be a valuable addition to current contraceptive options.

KEYWORD

Ortho Evra - Evra - transdermal contraception - pharmacokinetics - adherence

REFERENCES

  • 1 Abrams L, Skee D, Natarajan J, Wong F. An overview of the pharmacokinetics of a contraceptive patch.  Int J Gyn Obstet . 2000 (suppl 1);  70 [Abstract] (78)
    PubMedGoogle Scholar
  • 2 Abrams L, Skee D, Talluri K, Wong F. Bioavailability of 17-deacetylnorgestimate (17D-NGM) and ethinyl estradiol (EE) from a contraceptive patch.  FASEB J . 2000;  14 [Abstract] A1479
    PubMedGoogle Scholar
  • 3 Abrams L S, Skee D M, Natarajan J, Wong F A, Anderson G D. Pharmacokinetics of a contraceptive patch (Evra™/ Ortho Evra™) containing norelgestromin and ethinyl estradiol at four application sites.  Brit J Clin Pharmacol. 2001 In Press; 
    PubMedGoogle Scholar
  • 4 Dittrich R, Parker L, Rosen J B, Shangold G, Creasy G W, Fisher A C. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study.  Am J Obstet Gynecol. 2001 In press; 
    PubMedGoogle Scholar
  • 5 Abrams L, Skee D, Natarajan J, Wong F, Lasseter K C. Pharmacokinetics of multiple cycles of a contraceptive patch.  J Clin Pharmacol . 2000;  40 [Abstract] 1047
    PubMedGoogle Scholar
  • 6 Abrams L S, Skee D M, Wong F A, Anderson N J, Leese P T. Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.  J Clin Pharmacol . 2001;  41 1232-1237
    CrossrefPubMedGoogle Scholar
  • 7 Abrams L S, Skee D, Natarajan J, Hutman W, Wong F. Tetracycline HCL does not affect the pharmacokinetics of a contraceptive patch.  Int J Gyn Obstet . 2000 (suppl 1);  70 [Abstract] (57-58)
    PubMedGoogle Scholar
  • 8 Abrams L S, Skee D, Natarajan J, Lasseter K C, Wong F. Dose proportionality of a contraceptive patch.  Clin Pharmacol Ther . 2000;  67 [Abstract] 105
    PubMedGoogle Scholar
  • 9 Pierson R A, Hess A R, Archer D F. Effects of a contraceptive patch and 3 oral contraceptives on follicular development following incorrect dosing.  Int J Gyn Obstet . 2000 (suppl 1);  70 [Abstract] (78)
    PubMedGoogle Scholar
  • 10 Burkman R T, Borgatta L, Fisk F M, Darney P, Nelson A L, Hall N. A contraceptive patch and oral contraceptives produce similar effects on cervical mucus and endometrium.  Fertil Steril . 2000;  74 [Abstract] S69-S70
    PubMedGoogle Scholar
  • 11 Audet M-C, Moreau M, Koltun W D. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs.  an oral contraceptive: a randomized controlled trial. JAMA . 2001;  285 2347-2354
    PubMedGoogle Scholar
  • 12 Hedon B, Helmerhorst F M, Cronje H S, Shangold G, Fisher A, Creasy G. Comparison of efficacy, cycle control, compliance, and safety in users of a contraceptive patch vs.  an oral contraceptive. Int J Gyn Obstet . 2000 (suppl 1);  70 [Abstract] (78)
    PubMedGoogle Scholar
  • 13 Smallwood G H, Meador M L, Lenihan Jr P J, Shangold G A, Fisher A C, Creasy G W. Efficacy and safety of a transdermal contraceptive system.  Obstet Gynecol. 2001 In press; 
    PubMedGoogle Scholar
  • 14 Creasy G, Fisher A, Hall N, Shangold G. Effect of a contraceptive patch versus placebo (PBO) on serum lipid profile.  Fertil Steril . 2000;  74 [Abstract] S185
    PubMedGoogle Scholar
  • 15 Thorne E G, Roach J, Hall J, Creasy G. Lack of phototoxicity and photoallergy with a contraceptive patch.  FASEB J . 2000;  14 [Abstract] A1341
    PubMedGoogle Scholar
  • 16 Roach J, Thorne E G, Hall N, Creasy G. Evaluation of skin irritation in humans from a contraceptive patch.  FASEB J . 2000;  14 [Abstract] A1341
    PubMedGoogle Scholar
  • 17 Kluft C, Mayer G, Helmerhorst F M, Hall H, Creasy G. Comparison of the effects of a contraceptive patch and oral contraceptives on coagulation parameters.  Int J Gyn Obstet . 2000 (suppl 1);  70 [Abstract] (77)
    PubMedGoogle Scholar
  • 18 McGuire J L, Phillips A, Hahn D-W, Tolman E L, Flor S, Kafrissen M E. Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites.  Am J Obstet Gynecol . 1990;  163 2127-2131
    PubMedGoogle Scholar
  • 19 Alton K B, Hetyei N S, Shaw C, Patrick J E. Biotransformation of norgestimate in women.  Contraception . 1984;  29 19-29
    CrossrefPubMedGoogle Scholar
  • 20 Madden S, Back D J. Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro.  J Steroid Biochem Mol Biol . 1991;  38 497-503
    CrossrefPubMedGoogle Scholar
  • 21 Fotherby K. Pharmacokinetics of ethynyloestradiol in humans.  Methods Find Exp Clin Pharmacol . 1982;  4 133-141
    PubMedGoogle Scholar
  • 22 Stockley I. Interactions with oral contraceptives.  J Pharm . 1976;  216 140-143
    PubMedGoogle Scholar
  • 23 Back D J, Orme ML'E. Drug interactions. In: Goldzieher JW, Fotherby K, eds. Pharmacology of the Contraceptive Steroids New York: Raven Press 1994: 407-425
    Google Scholar
  • 24 Bolt H M. Interactions between clinically used drugs and oral contraceptives.  Environ Health Perspect . 1994 (suppl 9>;  102 (35-38)
    PubMedGoogle Scholar
  • 25 Moghissi K S. The cervix in infertility.  Clin Obstet Gynecol . 1979;  22 27-42
    PubMedGoogle Scholar
  • 26 Rosenberg M J, Waugh M S, Burnhill M S. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation.  Fam Plann Perspect . 1998;  30 89-104
    PubMedGoogle Scholar
  • 27 Potter L, Oakley D, de Leon-Wong E, Canamar R. Measuring compliance among oral contraceptive users.  Fam Plann Perspect . 1996;  28 154-158
    PubMedGoogle Scholar
  • 28 Rosenberg M J, Waugh M S, Meehan T E. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation.  Contraception . 1995;  51 283-288
    CrossrefPubMedGoogle Scholar
  • 29 Trussell J, Kowal D. The essentials of contraception: efficacy, safety, and personal considerations. In: Hatcher RA, Trussell J, Stewart F, et al, eds. Contraceptive Technology New York: Ardent Media Inc. 1998: 211-247
    Google Scholar
  • 30 National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II).  Circulation . 1994;  89 1329-1445
    PubMedGoogle Scholar
      >